Amgen (NASDAQ: AMGN) has scheduled a webcasted conference call for the investment community on Tuesday, September 24, 2024, at 1:30 p.m. PT. The purpose of the call is to discuss new topline clinical data from the rocatinlimab (AMG 451/KHK4083) and UPLIZNA® (inebilizumab-cdon) Phase 3 programs. Jay Bradner, the executive vice president of Research and Development and chief scientific officer at Amgen, will be joined by other team members during the call.
The webcast will be accessible to the news media, investors, and the general public through Amgen’s website at www.amgen.com under the Investors section. Additionally, the webcast will be archived and available for replay for a minimum of 90 days after the event. Detailed information about presentation times, webcast availability, and relevant links can be found on Amgen’s Investor Relations Events Calendar.
Amgen is a leading biotechnology company that focuses on discovering, developing, manufacturing, and delivering innovative medicines to combat challenging diseases globally. With over 40 years of experience, Amgen has been at the forefront of the biotechnology industry, leveraging technology and genetic data to drive scientific advancements. The company’s pipeline includes treatments for cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases.
In recognition of its innovative work, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company in 2024. The company was also recognized as one of “America’s Best Large Employers” by Forbes. Amgen is part of the Dow Jones Industrial Average® and the Nasdaq-100 Index®, highlighting its position as a key player in the biopharmaceutical industry.
For more information about Amgen and its upcoming conference call, visit Amgen.com and follow the company on various social media platforms. If you are interested in participating in the conference call or accessing the webcast, be sure to visit Amgen’s website for more details.
As Amgen continues to drive innovation in the biotechnology sector, the upcoming conference call presents an opportunity for investors, the media, and the public to gain insights into the latest clinical data and advancements in the field of rare diseases and inflammation. Stay tuned for valuable updates and information following the conference call.
